Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
filingDate |
2021-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7af467df397a88148580d7827f192f5e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_028b11c8f8afc892291c4dea11073bc8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eeacad19c17c541136fc0726e821add http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd146b741c984af76c216f21b414f5a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da674eaf426ae3bf53c4447bdaa35fe9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da231e406751dbeb632807d254edfa82 |
publicationDate |
2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2021230246-A1 |
titleOfInvention |
Use of inhibitory chimeric receptors to prevent t cell-induced blood brain barrier damage |
abstract |
Neurotoxicity associated with CD19-targeted CAR-T therapy is reduced by including an inhibitory CAR (iCAR) in the CAR-T cell, wherein the iCAR specifically recognizes an antigen specific for or associated with neurovascular mural cells (e.g. pericytes or vSMC). |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11648270-B2 |
priorityDate |
2020-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |